More publicity for RAP :) ResApp shares boosted by test results...

More publicity for RAP

ResApp shares boosted by test results

• THE AUSTRALIAN
• NOVEMBER 10, 2015 3:56PM

Sarah-Jane Tasker
Reporter
Sydney

ResApp CEO Tony Keating. Source: Supplied

Telehealth minnow ResApp Health has enjoyed a strong lift in a gloomy Australian market after announcing near perfect accuracy of its app in diagnosing respiratory diseases.
Shares in the company (NLS), which were in a trading halt ahead of the announcement, were up 19 per cent at 9.3c.

The app, which is being tested in a paediatric clinical study at Joondalup Health Campus and Princess Margaret Hospital in Perth, allows doctors to diagnose respiratory diseases such as pneumonia, bronchitis and asthma through a cough into a smartphone.

Users cough into the phone’s microphone from up to two metres away, and ResApp’s algorithms analyse the sound of the cough. The app looks for signatures in that cough and matches those signatures to respiratory diseases.

The latest preliminary results, based on an updated 338 subject dataset, demonstrated high levels of accuracy for distinguishing patients with bronchiolitis (100 per cent accuracy), croup (99 per cent) or upper respiratory tract infection (96 per cent) from subjects with no discernible respiratory disease.

“The release of this additional data is another significant step forward in our development of a complete respiratory disease diagnostic tool that provides instant answers and seamlessly integrates into telehealth platforms,” Dr Tony Keating, chief executive of ResApp Health, said.

ResApp said the results demonstrated the potential for the platform to differentially diagnose respiratory disease, with accuracy of 89 per cent to 99 per cent for the range of diseases considered.

“These results demonstrate the potential to accurately differentially diagnose respiratory disease in children in a novel way with meaningful consequences for selecting the correct treatment option,” Dr Paul Porter, paediatric emergency physician, Princess Margaret Hospital and clinical adviser to ResApp, said.

http://www.theaustralian.com.au/bus...-by-test-results/story-fn91v9q3-1227603500580